On September 27, 2023 Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, reported that the company will participate in the Emerging Growth Conference being held October 4 and 5, 2023 (Press release, Akari Therapeutics, SEP 27, 2023, View Source [SID1234635441]). President and CEO Rachelle Jacques will present an overview of the company and its lead asset nomacopan, a bispecific inhibitor of complement C5 and leukotriene B4 (LTB4), on October 4, 2023 from 11:25 am to 11:55 am ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Register for the presentation here.

Questions may be submitted in advance at [email protected].

On September 27, 2023 Adcentrx Therapeutics ("Adcentrx"), a biotechnology company dedicated to revolutionizing Antibody-Drug Conjugate (ADC) therapeutics for cancer and other life-threatening diseases, reported the first patient dosed in the Phase 1a/b study of ADRX-0706 for the treatment of advanced solid tumors (Press release, Adcentrx Therapeutics, SEP 27, 2023, View Source [SID1234635440]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to announce this important milestone for Adcentrx that marks our transition from the discovery stage into a clinical stage company," said Hui Li, Ph.D., Founder and Chief Executive Officer of Adcentrx. "We are enthusiastic about the potential of ADRX-0706 to address the unmet needs of patients with Nectin-4 expressing cancers."

The first-in-human Phase 1a/b clinical trial of ADRX-0706 is an open-label, multicenter dose escalation and dose expansion study. The study is enrolling patients with select advanced solid tumors. The primary objectives of the study are to characterize the safety and tolerability and to determine the optimal dose of ADRX-0706. The company expects an initial data readout in the middle of 2024.

About ADRX-0706

ADRX-0706 is an ADC product candidate discovered by Adcentrx. The antibody component targets Nectin-4, a cell surface adhesion protein over-expressed in multiple human cancers and associated with poor disease prognosis. The ADC is produced using Adcentrx’s proprietary i-Conjugation technology and novel tubulin inhibitor payload, AP052, to generate an ADC with a drug-antibody ratio of eight (DAR 8). ADRX-0706 has a favorable pharmacokinetic and safety profile in preclinical models, and has demonstrated significant efficacy across a variety of tumor indications.

On September 27, 2023 Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, reported details of an abstract accepted for poster presentation at the upcoming Society of Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 38th Annual Meeting, which will be held in San Diego, November 3-5, 2023 (Press release, Actinium Pharmaceuticals, SEP 27, 2023, View Source [SID1234635439]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the SITC (Free SITC Whitepaper) poster presentation:

Abstract Title: Preclinical evaluation of lintuzumab-Ac225, a CD33 antibody radioconjugate targeting myeloid-derived suppressor cells
Abstract Number: 1166
Session: November 4, 9:00 AM – 8:30 PM PT, Exhibit Halls A and B1

On September 26, 2023 A-Alpha Bio (A-Alpha), a synthetic biology and machine learning company that measures and engineers protein-protein interactions, reported the expansion of their collaboration with Amgen’s Induced Proximity Platform to characterize interactions between ligases and molecular glue targets for protein degradation (Press release, A-Alpha Bio, SEP 26, 2023, View Source [SID1234636945]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As part of a research collaboration initiated in 2022 with Amgen, a leading biotechnology company, A-Alpha discovered several weakly interacting ligase-target pairs between a list of Amgen’s targets and A-Alpha’s proprietary library of E3 ubiquitin ligases. Following review of the results from the initial collaboration and additional work carried out by Amgen, A-Alpha and Amgen have agreed to an expanded collaboration. Under the expanded collaboration agreement, A-Alpha will further interrogate selected pairs to evaluate glueability and provide structural insights expected to enable rational design of molecular glue degraders. A-Alpha Bio will receive an upfront payment and will be eligible for milestones and a royalty on product sales resulting from licensed ligase-target pairs.

"Our work with Amgen over the past six months has been exciting and fruitful. We have enjoyed collaborating with an incredible industry-leading team on this major area of interest," said David Younger, CEO and Co-Founder of A-Alpha Bio. "We look forward to expanding our collaboration and moving into the validation of glueability and the generation of data to inform rational molecular glue discovery. Combining our technology and expertise with Amgen’s has the potential to generate high-impact therapeutics and advance our mission to improve human health."

On September 26, 2023, Roivant Sciences Ltd. (the "Company") reported to have entered into common share purchase and sale agreements (collectively, the "Purchase and Sale Agreements") with certain institutional investors, pursuant to which the Company agreed to issue and sell an aggregate of 19,600,685 of the Company’s common shares, par value $0.0000000341740141 per share (the "Common Shares"), at purchase price of $10.21 for each Common Share for aggregate gross proceeds of approximately $200.1 million (the "Registered Direct Offering") (Filing, 8-K, Roivant Sciences, SEP 26, 2023, View Source [SID1234635548]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Registered Direct Offering was made pursuant to a prospectus supplement to the Company’s effective shelf registration statement on Form S-3 (Registration No. 333-267503) (the "Shelf Registration Statement"). The Company expects to use the net proceeds from the Registered Direct Offering to make an investment into its subsidiary, Immunovant, Inc., and for working capital and other general corporate purposes.

The legal opinion of Conyers Dill & Pearman Limited relating to the legality of the issuance and sale of the Common Shares in the Registered Direct Offering is attached as Exhibit 5.1 to this Current Report on Form 8-K.

The foregoing summary of the Purchase and Sale Agreements is qualified in its entirety by reference to the Form of Common Share Purchase and Sale Agreement, which is filed as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.